-
公开(公告)号:US20250066507A1
公开(公告)日:2025-02-27
申请号:US18798557
申请日:2024-08-08
Applicant: Genmab A/S
Inventor: Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , OyewaleV O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号:US20230027495A1
公开(公告)日:2023-01-26
申请号:US17775279
申请日:2020-11-06
Applicant: Genmab A/S , MSD International GmbH
Inventor: Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号:US20220088191A1
公开(公告)日:2022-03-24
申请号:US17053753
申请日:2019-05-07
Applicant: Genmab A/S , MSD International GmbH
Inventor: Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
IPC: A61K39/395 , A61K47/68 , A61P35/00
Abstract: The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody comprising the CDRs of pembrolizumab and the antibody-drug conjugate that binds to TF comprising monomethyl auristatin E and the CDRs of tisotumab (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
公开(公告)号:US20210107980A1
公开(公告)日:2021-04-15
申请号:US17053346
申请日:2019-05-07
Applicant: Genmab A/S
Inventor: Reshma Abdulla RANGWALA , Esther C.W. BREIJ , Sandra VERPLOEGEN , Oyewale O. ABIDOYE , Leonardo Viana NICACIO , Anthony CAO , Shyra GARDAI
Abstract: The invention provides an anti-PD-1 antibody in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as breast cancer and cervical cancer. The invention also provides compositions and kits comprising the anti-PD-1 antibody and the antibody-drug conjugate that binds to TF (e.g., tisotumab vedotin) for use in treating cancer, such as breast cancer and cervical cancer.
-
-
-